Samsung Biologics Labor Dispute Continues: Union to Launch Compliance Strike

The ongoing labor dispute at Samsung Biologics continues to escalate, with the latest round of negotiations, mediated by the Ministry of Employment and Labor, failing to bridge the significant gap between the union's demands and the company's offers. The union's decision to proceed with a "compliance strike" starting June 6, where they will refuse overtime and holiday work, signals a hardening of their stance and a potential disruption to the company's operations.

“

There are differences in opinions, and the areas that have been narrowed down are currently none.

Union representatives expressed dissatisfaction with the company's negotiation team, noting the absence of CEO John Rim and the presence of only mid-level executives. This was perceived as a lack of genuine commitment to resolving the dispute, reducing the talks to mere procedural dialogue rather than substantive negotiation. The union's demands are substantial: a 14% wage increase, a bonus equivalent to 20% of operating profit, and a 30 million won incentive for each employee. They are also pushing for greater transparency in performance evaluations and promotion criteria, as well as job security.

“

It could only be a simple procedural conversation, not a substantive negotiation to resolve the situation.

Samsung Biologics, on the other hand, has offered a 6.2% wage increase and a one-time bonus of 6 million won. This offer falls significantly short of the union's expectations, highlighting the deep-seated disagreement over compensation and working conditions. The union has been on a partial strike for three days and a full strike since June 1, demonstrating their resolve.

“

The union is demanding a wage increase (14%) and a performance bonus (20% of operating profit), as well as a 30 million won incentive per employee.

Further talks are scheduled, with both sides set to meet again on June 5 and June 8, with the Ministry of Employment and Labor's involvement. However, the current impasse and the union's planned compliance strike suggest that a swift resolution is unlikely. The situation at Samsung Biologics reflects a broader trend of labor activism in South Korea, where unions are increasingly assertive in demanding better wages and working conditions, particularly in large conglomerates.

“

Samsung Biologics, on the other hand, is sticking to a 6.2% wage increase and a one-time bonus of 6 million won.